on CureVac (NASDAQ:CVAC)
CureVac Announces Voting Results of General Meeting
TÜBINGEN, Germany/BOSTON, USA – June 24, 2024 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing transformative mRNA-based medicines, announced the results of its annual general meeting.
The shareholders approved all proposals, including the appointment of Thaminda Ramanayake and the reappointment of Malte Greune to the Management Board, effective June 24th, 2024. Jean Stéphenne and Mathias Hothum were reappointed to the Supervisory Board, and Birgit Hofmann joined as a new member. Additionally, KPMG Accountants N.V. was reappointed as external auditors for the financial year 2024.
A detailed table of the votes cast will be released in the coming days.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CureVac news